Search research articles
Contact Us
Filters
Showing results (411-420 of 427) with videos related to
Page
of 43
Sort By:
Nature Communications
|
August 17, 2023
Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level
Lukas John, Alexandra M Poos, Alexander Brobeil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2024
Genomic Classification and Individualized Prognosis in Multiple Myeloma
Francesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu, et al.
Blood
|
June 10, 2018
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Brian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
Hemasphere
|
November 27, 2025
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
Niels W C J van de Donk, Philippe Moreau, Jesus F San-Miguel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 21, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial
Jia Xiang Jin, Varun R Ginde, Stefanie Huhn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2026
Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial
Jia Xiang Jin, Varun R Ginde, Stefanie Huhn, et al.
Lancet (London, England)
|
June 14, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial
Meletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2025
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
Hervé Avet-Loiseau, Faith E Davies, Mehmet K Samur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 25, 2025
Erratum: International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
Hervé Avet-Loiseau, Faith E Davies, Mehmet K Samur, et al.
Nature Medicine
|
March 25, 2026
Enhanced dynamic risk stratification of smoldering multiple myeloma
Floris Chabrun, Daniel E Schwartz, Susanna Gentile, et al.
Page
of 43
Search research articles
Search
Showing results (411-420 of 427) with videos related to
Sort By:
Page
of 43
Nature Communications
|
August 17, 2023
Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level
Lukas John, Alexandra M Poos, Alexander Brobeil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2024
Genomic Classification and Individualized Prognosis in Multiple Myeloma
Francesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu, et al.
Blood
|
June 10, 2018
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Brian A Walker, Konstantinos Mavrommatis, Christopher P Wardell, et al.
Hemasphere
|
November 27, 2025
Sequencing BCMA- and GPRC5D-targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
Niels W C J van de Donk, Philippe Moreau, Jesus F San-Miguel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 21, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial
Jia Xiang Jin, Varun R Ginde, Stefanie Huhn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2026
Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial
Jia Xiang Jin, Varun R Ginde, Stefanie Huhn, et al.
Lancet (London, England)
|
June 14, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial
Meletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2025
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
Hervé Avet-Loiseau, Faith E Davies, Mehmet K Samur, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 25, 2025
Erratum: International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
Hervé Avet-Loiseau, Faith E Davies, Mehmet K Samur, et al.
Nature Medicine
|
March 25, 2026
Enhanced dynamic risk stratification of smoldering multiple myeloma
Floris Chabrun, Daniel E Schwartz, Susanna Gentile, et al.
Page
of 43